Preliminary evaluation of a new psychotropic drug, lenperone, in the treatment of acute schizophrenia.

Abstract

An open trial of a new psychotropic drug, lenperone, was carried out in 10 patients with acute schizophrenia. The duration of treatment was 28 days and the maximum dose administered was 60 mg per day. A pronounced antipsychotic effect was seen in half of the patients, although all 10 patients showed a pharmacological response to the drug. The incidence of side-effects was low. Haematological, biochemical and electrocardiographic tests failed to demonstrate any abnormality due to treatment.

• Authors: B R Nakra, C J Jones, A K Majumdar, R Gaind
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 4 Issue 8 Pg. 529-34 ( 1977) ISSN: 0300-7995 [Print] England
• PMID: 559569 (Publication Type: Journal Article)

Chemical References

• Butyrophenones

Topics

• Acute Disease
• Adult
• Butyrophenones (administration & dosage, adverse effects, therapeutic use)
• Evaluation Studies as Topic
• Female
• Humans
• Male
• Middle Aged
• Psychiatric Status Rating Scales
• Schizophrenia (drug therapy)